Suchergebnisse - "Andreeff, Michael"

PubPharm (812)

11

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

enthalten in: Science advances | 2023

von Nishida, Y. | Ishizawa, J. | Ayoub, E. | +17

12

Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia

enthalten in: ResearchSquare.com | 2023

von Akiyama, H. | Zhao, R. | Ostermann, L. | +11

13

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

enthalten in: Blood advances | 2023

von Figueroa, M. | Ma, H. | Alfayez, M. | +12

14

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

enthalten in: Haematologica | 2023

von Jia, Y. | Han, L. | Ramage, C. | +17

15

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells

enthalten in: Blood | 2023

von Carter, B. | Mak, P. | Muftuoglu, M. | +22

CommentIn: Blood. 2023 Sep 21;142(12):1031-1032. - PMID 37733379

16

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

enthalten in: Nature communications | 2023

von Ebner, J. | Schmoellerl, J. | Piontek, M. | +12

17

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model

enthalten in: Haematologica | 2023

von Carter, B. | Mak, P. | Tao, W. | +6

18

Determination of Radiation Exposure of Individuals in the Population by Patients after Radioiodine Therapy - Comparison of two Measurement Systems

enthalten in: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin | 2023

von Hartmann, H. | Andreeff, M. | Claußnitzer, J. | +2

19

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

enthalten in: Blood advances | 2023

von Bazinet, A. | Kadia, T. | Short, N. | +24

20

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

enthalten in: Journal of hematology & oncology | 2023

von Short, N. | Muftuoglu, M. | Ong, F. | +24